ES2379513T3 - Receptor de proteína de la neurotoxina botulínica A y sus utilizaciones - Google Patents

Receptor de proteína de la neurotoxina botulínica A y sus utilizaciones Download PDF

Info

Publication number
ES2379513T3
ES2379513T3 ES06806613T ES06806613T ES2379513T3 ES 2379513 T3 ES2379513 T3 ES 2379513T3 ES 06806613 T ES06806613 T ES 06806613T ES 06806613 T ES06806613 T ES 06806613T ES 2379513 T3 ES2379513 T3 ES 2379513T3
Authority
ES
Spain
Prior art keywords
bont
polypeptide
homo sapiens
antibody
synaptic vesicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06806613T
Other languages
English (en)
Spanish (es)
Inventor
Andreas Rummel
Thomas Binz
Stefan Mahrhold
Johannes Wilhelm Bigalke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toxogen GmbH
Original Assignee
Toxogen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toxogen GmbH filed Critical Toxogen GmbH
Application granted granted Critical
Publication of ES2379513T3 publication Critical patent/ES2379513T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES06806613T 2005-10-28 2006-10-30 Receptor de proteína de la neurotoxina botulínica A y sus utilizaciones Active ES2379513T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005051789 2005-10-28
DE102005051789.7A DE102005051789B4 (de) 2005-10-28 2005-10-28 Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
PCT/EP2006/010420 WO2007048638A2 (de) 2005-10-28 2006-10-30 Der botulinus neurotoxin a proteinrezeptor und seine anwendungen

Publications (1)

Publication Number Publication Date
ES2379513T3 true ES2379513T3 (es) 2012-04-26

Family

ID=37770829

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06806613T Active ES2379513T3 (es) 2005-10-28 2006-10-30 Receptor de proteína de la neurotoxina botulínica A y sus utilizaciones

Country Status (12)

Country Link
US (1) US8476024B2 (https=)
EP (1) EP1940874B1 (https=)
JP (1) JP2009513118A (https=)
KR (1) KR20080068069A (https=)
AT (1) ATE539088T1 (https=)
AU (1) AU2006308122B2 (https=)
CA (1) CA2627457C (https=)
DE (1) DE102005051789B4 (https=)
ES (1) ES2379513T3 (https=)
NZ (1) NZ567312A (https=)
WO (1) WO2007048638A2 (https=)
ZA (1) ZA200803403B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US7985554B2 (en) 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US9000131B2 (en) * 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US8771707B2 (en) * 2008-09-30 2014-07-08 Wisconsin Alumni Research Foundation Botulinum neurotoxin E receptors and uses thereof
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
UA116985C2 (uk) 2012-05-30 2018-06-11 Президент Енд Феллоуз Оф Гарвард Колледж Рекомбінантний ботулінічний нейротоксин
WO2014079495A1 (en) * 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
PT3274364T (pt) 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
KR101670188B1 (ko) 2015-11-09 2016-10-27 충북대학교 산학협력단 보툴리눔 신경독소 ｅ형에 특이적인 폴리펩타이드 및 이의 용도
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
KR101958312B1 (ko) * 2017-09-06 2019-07-02 국방과학연구소 보툴리눔 a형 독소에 대한 항체
IL272002A (en) 2020-01-13 2021-07-29 The Israel Institute Of Biological Res Iibr Methods for identifying anti clostridial neurotoxin compounds
WO2023210585A1 (ja) * 2022-04-25 2023-11-02 株式会社Jiksak Bioengineering 標的化剤
WO2025089343A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプス小胞糖タンパク質２ｃ抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016233A2 (en) 2002-10-31 2005-02-24 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
CA2484115C (en) * 2002-12-03 2007-01-30 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof

Also Published As

Publication number Publication date
US8476024B2 (en) 2013-07-02
AU2006308122B2 (en) 2011-06-30
NZ567312A (en) 2011-09-30
EP1940874A2 (de) 2008-07-09
EP1940874B1 (de) 2011-12-28
DE102005051789B4 (de) 2014-08-07
DE102005051789A1 (de) 2007-05-10
WO2007048638A2 (de) 2007-05-03
KR20080068069A (ko) 2008-07-22
US20090252722A1 (en) 2009-10-08
ZA200803403B (en) 2009-02-25
CA2627457C (en) 2014-05-13
JP2009513118A (ja) 2009-04-02
WO2007048638A3 (de) 2007-07-26
CA2627457A1 (en) 2007-05-03
AU2006308122A1 (en) 2007-05-03
ATE539088T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
ES2379513T3 (es) Receptor de proteína de la neurotoxina botulínica A y sus utilizaciones
Rummel et al. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation‐dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor
Binz et al. Cell entry strategy of clostridial neurotoxins
Rummel et al. The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction
Vaidyanathan et al. Proteolysis of SNAP‐25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme‐substrate complexes and cleavage
Dong et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells
Capasso et al. Extensive digestion of Na+, K (+)-ATPase by specific and nonspecific proteases with preservation of cation occlusion sites.
Gommel et al. Recruitment to Golgi membranes of ADP‐ribosylation factor 1 is mediated by the cytoplasmic domain of p23
Herreros et al. Tetanus toxin fragment C binds to a protein present in neuronal cell lines and motoneurons
US8093044B2 (en) Methods for identifying inhibitors of botulinum neurotoxins
Weller et al. Chains and fragments of tetanus toxin: separation, reassociation and pharmacological properties
Shainskaya et al. Evidence that the cation occlusion domain of Na/K-ATPase consists of a complex of membrane-spanning segments. Analysis of limit membrane-embedded tryptic fragments.
Maes et al. Mapping of the ATP-binding sites on inositol 1, 4, 5-trisphosphate receptor type 1 and type 3 homotetramers by controlled proteolysis and photoaffinity labeling
Petrenko et al. Polypeptide composition of the alpha-latrotoxin receptor. High affinity binding protein consists of a family of related high molecular weight polypeptides complexed to a low molecular weight protein.
Young et al. An amino-terminal domain containing hydrophobic and hydrophilic sequences binds the signal recognition particle receptor α subunit to the β subunit on the endoplasmic reticulum membrane
Quesenberry et al. Role of conserved and nonconserved residues in the Ca (2+)-dependent carbohydrate-recognition domain of a rat mannose-binding protein. Analysis by random cassette mutagenesis.
Antolik et al. The actin binding domain of ACF7 binds directly to the tetratricopeptide repeat domains of rapsyn
Yammani et al. Identification and characterization of two distinct ligand binding regions of cubilin
Fournier et al. Drosophila acetylcholinesterase: expression of a functional precursor in Xenopus oocytes
Pagano et al. Cystic fibrosis transmembrane regulator fragments with the Phe508 deletion exert a dual allosteric control over the master kinase CK2
Burns et al. Insights into the mechanisms by which clostridial neurotoxins discriminate between gangliosides
Klaerke Purification and characterization of epithelial Ca2+-activated K+ channels
Bonza et al. Plant and animal type 2B Ca2+-ATPases: evidence for a common auto-inhibitory mechanism
De Donatis et al. A single ClpS monomer is sufficient to direct the activity of the ClpA hexamer
Buzzatto et al. Expression, purification and application of a recombinant, membrane permeating version of the light chain of botulinum toxin B